displaying 1 - 3 records in total 3
    records per page

    High prevalence SERO of deep venous thrombosis HP deep venous thrombosis MESHD in non-severe COVID-19 patients hospitalized for a neurovascular disease MESHD

    Authors: Olivier Rouyer; Irene-Nora Pierre-Paul; Amadou Balde; Damaris Jupitet; Daniela Bindila; Bernard Geny; Valerie Wolff

    doi:10.1101/2020.09.03.20187344 Date: 2020-09-05 Source: medRxiv

    Abstract Introduction: Severe SARS-CoV-2 infection MESHD, responsible for COVID-19, is accompanied by venous thromboembolic MESHD events particularly in intensive care unit. In non-severe COVID-19 patients affected by neurovascular diseases MESHD, the prevalence SERO of deep venous thrombosis HP deep venous thrombosis MESHD ( DVT MESHD) is unknown. The aim of or study was to report data obtained after systematic Doppler ultrasound scanning ( DUS MESHD) of lower limbs in such patients. Methods: Between March 20 and May 2, 2020, consecutive patients with neurovascular diseases MESHD with non-severe COVID-19 were investigated with a systematic bedside DUS. Results Thirteen patients were enrolled including 10 acute ischemic strokes MESHD ischemic strokes HP, one transient ischemic attack HP ischemic MESHD attack, one cerebral venous thrombosis HP cerebral venous thrombosis MESHD and one haemorrhagic stroke MESHD stroke HP. At admission, the median National Institute of Health Stroke HP Stroke MESHD Scale (NIHSS) was of 6 (IQR, 0-20). We found a prevalence SERO of 38.5% of asymptomatic TRANS calves DVT MESHD (n=5) during the first week after admission despite thromboprophylaxis. Among them, one patient had a symptomatic pulmonary embolism HP pulmonary embolism MESHD. Two patients died during hospitalization but the outcome was favourable in the others with a discharge median NIHSS of 1 (IQR, 0-11). Discussion/Conclusion: Despite thromboprophylaxis, systematic bedside DUS showed a high prevalence SERO of 38.5% of DVT MESHD in non-severe COVID-19 patients with neurovascular diseases MESHD. Therefore, we suggest that this non-invasive investigation should be performed in all patients of this category.

    Deep Venous Thrombosis HP Deep Venous Thrombosis MESHD in COVID-19 Patients: A Cohort Analysis

    Authors: Yi Guo; Yun You; Ke Hu; Fei Cai; Yiqing Li; Mingxing Xie; Lu Yang; Dawei Ye; Ken Ling; Sanjay Misra; Weici Wang; chuanqi cai

    doi:10.21203/rs.3.rs-39414/v1 Date: 2020-07-01 Source: ResearchSquare

    BackgroundDeep venous thrombosis HP venous thrombosis MESHD (DVT) is a severe complication of the coronavirus disease MESHD 2019 (COVID-19). It may interfere with COVID-19 treatment and delay the recovery, but there is less data about the anticoagulant therapy and sex difference of VTE MESHD in patients with COVID-19. The purpose of this study is to study the prevalence SERO, risk factors, anticoagulant therapy and sex difference of deep venous thrombosis HP deep venous thrombosis MESHD ( DVT MESHD) in patients with COVID-19.MethodsThe enrolled 121 patients were confirmed positive for COVID-19. All suspected patients with a high Caprini index (≥4) or PADUA index (≥4) received color Doppler Ultrasound (US) to screen DVT MESHD in both lower extremities. Clinical characteristics of DVT MESHD-COVID-19 patients were analyzed. Multivariate logistic regression was performed to identify risk factors related to DVT MESHD in COVID-19 patients. The distribution of DVT MESHD locations, anticoagulation therapy with sex difference, and the outcomes were also analyzed.ResultsDVT was found in 48% asymptomatic TRANS COVID-19 patients with increased PAUDA index or Caprini index by US scanning. Multivariate logistic regression determined that age TRANS, CRP and baseline D-dimer were risk factors among COVDI-19 patients. Although the most common DVT MESHD location was infrapopliteal (Class I and Class II), higher mortality in DVT MESHD-COVID-19 patients was confirmed. DVT MESHD-COVID-19 patients presented significant increases in the CRP, neutrophil count and D-dimer throughout the whole inpatient period compared to non- DVT MESHD-COVID-19 patients. Although anticoagulation therapy accelerated the recovery of lymphocytopenia condition MESHD in DVT MESHD patients, men DVT MESHD-COVID-19 patients showed higher CRP and neutrophil count vs. lymphocyte count (N/L) ratio but lower lymphocyte count compared to women DVT MESHD-COVID-19 patients. ConclusionsDVT is common in COVID-19 patients with high risk factors, especially for older age TRANS, higher CRP and baseline D-dimer populations. It is important to consider sex differences in the anticoagulant therapy among DVT MESHD-COVID-19 patients.

    The validation of the original and modified Caprini score in COVID-19 patients

    Authors: Sergey Tsaplin; Ilya Schastlivtsev; Kirill Lobastov; Sergey Zhuravlev; Victor Barinov; Joseph Caprini

    doi:10.1101/2020.06.22.20137075 Date: 2020-06-23 Source: medRxiv

    Objective. The study aimed to validate the original Caprini score and its modifications considering coronavirus disease MESHD (COVID-19) as a severe prothrombotic condition MESHD in patients admitted to the hospital with confirmed infection TRANS infection MESHD. Methods. The relevant data were extracted from the electronic medical records with the implemented Caprini score and were evaluated retrospectively. The score was calculated twice: by the physician at the admission and by the investigator at discharge or after death. The second calculation at discharge, considered additional risk factors that occurred during inpatient treatment. Besides the original Caprini score (a version of 2005), the modified version added the elevation of D-dimer and specific scores for COVID-19 as follows: 2 points for asymptomatic TRANS, 3 points for symptomatic and 5 points for symptomatic infection MESHD with positive D-dimer, were evaluated in a retrospective manner. The primary endpoint was symptomatic venous thromboembolism MESHD thromboembolism HP ( VTE MESHD) confirmed by appropriate imaging testing or dissection. The secondary endpoint included the unfavorable outcome as a combination of symptomatic VTE MESHD, admission to the intensive care unit, the requirement for invasive mechanical ventilation, and death MESHD. The association of eight different versions of the Caprini score with outcomes was evaluated. Results. Totally 168 patients (83 males TRANS and 85 females TRANS at the age TRANS of 58.3{+/-}12.7 years old) were admitted to the hospital between April 30 and May 29, 2020, and were discharged or died up to the time of data analysis. The original Caprini score varied between 2-12 (5.4{+/-}1.8) at the admission and between 2-15 (5.9{+/-}2.5) at discharge or death MESHD. The presence of the virus increased these scores and resulted in an increased score with the maximal value for those including COVID-19 points (10.0{+/-}3.0). Patients received prophylactic (2.4%), intermediate (76.8%), or therapeutic (20.8%) doses of enoxaparin. Despite this, the symptomatic VTE MESHD was detected in 11 (6.5%) and unfavorable outcomes in 31 (18.5%) patients. The Caprini score of all eight versions demonstrated a significant association with VTE MESHD with the highest predictability for the original scale when assessed at discharge. Supplementation of the original score by elevated D-dimer improved predictability only at the admission. Four versions of the Caprini score calculated at the admission had a significant correlation with the unfavorable outcome with the minor advantages of specific COVID-19 points. Conclusion. The study identified a significant correlation between the Caprini score and the risk of VTE MESHD or unfavorable outcomes in COVID-19 patients. All models, including specific COVID-19 scores, showed high predictability with minor differences.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.